middle.news
Amplia Therapeutics Accelerates Pancreatic Cancer Trials with Promising Interim Data
5:32am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Amplia Therapeutics Accelerates Pancreatic Cancer Trials with Promising Interim Data
5:32am on Monday 2nd of June, 2025 AEST
Key Points
Phase 2a ACCENT trial recruitment completed two months ahead of schedule
Interim data shows 13 confirmed partial responses in pancreatic cancer patients
Second trial combining narmafotinib with FOLFIRINOX progressing with positive FDA feedback
Strong cash position of $10.9 million at quarter end despite $2.7 million operating outflows
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE